Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs. Novo Nordisk has asked the FDA to block compounders from making versions ...

If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.